On Wednesday, Shares of Ultrapetrol (Bahamas) Limited (OTCMKTS:ULTR), added 4.35% and closed at $0.240 in the last trading session. The last trading range of the stock ranges between $0.20 and $0.29.
Celgene Corporation (NASDAQ:CELG), dropped -1.01% and closed at $119.69 in the last trading session. The last trading range of the stock ranges between $119.16 and $121.22. The company’s Market capitalization is $92.96 Billion with the total Outstanding Shares of 775.20 million. Celgene Corporation (CELG) recently declared findings from the ACTIVE phase 3b clinical trial of OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Washington, D.C. The trial met its primary endpoint of noteworthyimprovement in the proportion of patients achieving an ACR20 response at week 16 with OTEZLA as compared to placebo in patients with active psoriatic arthritis who have not formerly been treated with a biologic therapy.
The ACTIVE trial randomized 219 patients who may have had one prior conventional therapy and were not formerly treated with a biologic to either OTEZLA 30 mg twice daily (n=110) or placebo (n=109). An objective of the study was to determine the clinical effects of OTEZLA contrast with placebo, by examining efficacy outcomes at earlier time points than in previous studies.
“These findings show a separation from placebo as early as two weeks with oral OTEZLA in patients with psoriatic arthritis who have not been formerly treated with biologics,” said Dr. Jacob Aelion, director of the West Tennessee Research Institute and clinical professor of Medicine/Rheumatology at the University of Tennessee in Memphis. “Early responses at week 2 across several measures of disease activity, counting morning stiffness and enthesitis, were also seen at week 16.”